Fig. 6
The effect of rapamycin on metabolic profile of IDH1 mutant HT-1080 cells. Rapamycin treatment reduced the levels of two oncometabolites in parallel - lactate and 2-HG - in high glycolytic, IDH1 mutant fibrosarcoma cells. mTOR inhibition decreased metabolic capacity, the glycolysis and the glutaminolysis with remarkable downregulation of LDH-A and glutaminase enzyme expressions in HT-1080 cells (further explanation in the discussion)